Catastrophic Health Expenditure (CHE) among Cancer Population in a Middle Income Country with Universal Healthcare Financing.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Jun 2023
Historique:
received: 01 12 2022
medline: 30 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

The study investigated healthcare expenditure from the perspective of cancer patients, to determine the level of Catastrophic Health Expenditure (CHE) and its associated factors. This cross-sectional study was conducted in three Malaysian public hospitals namely Hospital Kuala Lumpur, Hospital Canselor Tuanku Muhriz and the National Cancer Institute using a multi-level sampling technique to recruit 630 respondents from February 2020 to February 2021. CHE was defined as incurring a monthly health expenditure of more than 10% of the total monthly household expenditure. A validated questionnaire was used to collect the relevant data. The CHE level was 54.4%. CHE was higher among patients of Indian ethnicity (P = 0.015), lower level education (P = 0.001), those unemployed (P < 0.001), lower income (P < 0.001), those in poverty (P < 0.001), those staying far from the hospital (P < 0.001), living in rural areas (P = 0.003), small household size (P = 0.029), moderate cancer duration (P = 0.030), received radiotherapy  treatment (P < 0.001), had very frequent treatment (P < 0.001), and without a Guarantee Letter (GL) (P < 0.001). The regression analysis identified significant predictors of CHE as lower income aOR 18.63 (CI 5.71-60.78), middle income aOR 4.67 (CI 1.52-14.41), poverty income aOR 4.66 (CI 2.60-8.33), staying far from hospital aOR 2.62 (CI 1.58-4.34), chemotherapy aOR 3.70 (CI 2.01-6.82), radiotherapy aOR 2.99 (CI 1.37-6.57), combination chemo-radiotherapy aOR 4.99 (CI 1.48-16.87), health insurance aOR 3.99 (CI 2.31-6.90), without GL aOR 3.38 (CI 2.06-5.40), and without health financial aids aOR 2.94 (CI 1.24-6.96). CHE is related to various sociodemographic, economic, disease, treatment and presence of health insurance, GL and health financial aids variables in Malaysia.

Sections du résumé

BACKGROUND BACKGROUND
The study investigated healthcare expenditure from the perspective of cancer patients, to determine the level of Catastrophic Health Expenditure (CHE) and its associated factors.
METHODS METHODS
This cross-sectional study was conducted in three Malaysian public hospitals namely Hospital Kuala Lumpur, Hospital Canselor Tuanku Muhriz and the National Cancer Institute using a multi-level sampling technique to recruit 630 respondents from February 2020 to February 2021. CHE was defined as incurring a monthly health expenditure of more than 10% of the total monthly household expenditure. A validated questionnaire was used to collect the relevant data.
RESULTS RESULTS
The CHE level was 54.4%. CHE was higher among patients of Indian ethnicity (P = 0.015), lower level education (P = 0.001), those unemployed (P < 0.001), lower income (P < 0.001), those in poverty (P < 0.001), those staying far from the hospital (P < 0.001), living in rural areas (P = 0.003), small household size (P = 0.029), moderate cancer duration (P = 0.030), received radiotherapy  treatment (P < 0.001), had very frequent treatment (P < 0.001), and without a Guarantee Letter (GL) (P < 0.001). The regression analysis identified significant predictors of CHE as lower income aOR 18.63 (CI 5.71-60.78), middle income aOR 4.67 (CI 1.52-14.41), poverty income aOR 4.66 (CI 2.60-8.33), staying far from hospital aOR 2.62 (CI 1.58-4.34), chemotherapy aOR 3.70 (CI 2.01-6.82), radiotherapy aOR 2.99 (CI 1.37-6.57), combination chemo-radiotherapy aOR 4.99 (CI 1.48-16.87), health insurance aOR 3.99 (CI 2.31-6.90), without GL aOR 3.38 (CI 2.06-5.40), and without health financial aids aOR 2.94 (CI 1.24-6.96).
CONCLUSIONS CONCLUSIONS
CHE is related to various sociodemographic, economic, disease, treatment and presence of health insurance, GL and health financial aids variables in Malaysia.

Identifiants

pubmed: 37378917
doi: 10.31557/APJCP.2023.24.6.1897
pmc: PMC10505870
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1897-1904

Références

Int J Equity Health. 2015 Sep 15;14:79
pubmed: 26370774
Asian Pac J Cancer Prev. 2012;13(2):421-5
pubmed: 22524800
BMC Health Serv Res. 2015 Jan 22;15:26
pubmed: 25608983
Bull World Health Organ. 2012 Sep 1;90(9):664-71
pubmed: 22984311
Lancet. 2012 Sep 8;380(9845):917-23
pubmed: 22959388
Int J Equity Health. 2015 May 14;14:46
pubmed: 25971679
Indian J Med Res. 2012 Oct;136(4):585-92
pubmed: 23168698
Health Res Policy Syst. 2011 Apr 06;9:16
pubmed: 21466714
Asia Pac Fam Med. 2017 Apr 4;16:5
pubmed: 28392749
Eur J Cancer Care (Engl). 2020 Jul;29(4):e13248
pubmed: 32495472
Asian Pac J Cancer Prev. 2022 May 01;23(5):1611-1618
pubmed: 35633545
Trop Med Int Health. 2014 Oct;19(10):1249-58
pubmed: 25040399
Cancer Med. 2020 Sep;9(18):6802-6812
pubmed: 32697427
Bull World Health Organ. 2013 Mar 1;91(3):207-16
pubmed: 23476093
Lancet Glob Health. 2018 Feb;6(2):e169-e179
pubmed: 29248367
PLoS One. 2015 May 05;10(5):e0125878
pubmed: 25941805
Asia Pac J Public Health. 2017 Sep;29(6):485-494
pubmed: 29019257
BMC Public Health. 2019 Jun 13;19(Suppl 4):551
pubmed: 31196024
BMC Int Health Hum Rights. 2014 Mar 05;14:5
pubmed: 24597486
Cancer J. 2020 Jul/Aug;26(4):281-286
pubmed: 32732669
PLoS One. 2016 Jan 21;11(1):e0146508
pubmed: 26795620
BMC Health Serv Res. 2009 Apr 28;9:69
pubmed: 19400939
Trop Med Int Health. 2011 Oct;16(10):1334-41
pubmed: 21752164
Glob Health Action. 2012 Dec 20;5:1-7
pubmed: 23273250
Int Health. 2017 Jan;9(1):29-35
pubmed: 28028130
Syst Rev. 2018 Sep 11;7(1):136
pubmed: 30205846
Asian Pac J Cancer Prev. 2014;15(6):2713-7
pubmed: 24761890
BMJ Open. 2016 Jul 05;6(7):e010992
pubmed: 27381206
BMC Med. 2015 Aug 18;13:190
pubmed: 26282128
Int J Epidemiol. 2008 Aug;37(4):758-65
pubmed: 18411201
Hum Reprod. 2013 Oct;28(10):2755-64
pubmed: 23878180
Healthcare (Basel). 2022 Oct 20;10(10):
pubmed: 36292545
Int J Health Policy Manag. 2016 Mar 14;5(7):417-423
pubmed: 27694669
Health Aff (Millwood). 2007 Jul-Aug;26(4):972-83
pubmed: 17630440
Lancet. 2003 Jul 12;362(9378):111-7
pubmed: 12867110

Auteurs

Sharifa Ezat Wan Puteh (SE)

Department of Public Health, Universiti Kebangsaan Malaysia, Malaysia.

Yang Rashidi Abdullah (YR)

Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia.

Azimatun Noor Aizuddin (AN)

Department of Community Health, Faculty of Medicine, Hospital Canselor Tuanku Muhriz, Jalan Yaakob Latif Bandar Tun Razak, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH